Background: Cancer is a pathogenesis that happens when modification in collections of normally occurring cells inside the human body occurs leading to non-controlled growth causing a lump called the tumor; this applies to all types of cancers except leukemia (cancer of the blood). Doxorubicin (DOX) is one of the highly effective anti-neoplastic drugs of the anthracycline's family used to treat many pediatric and adult cancers, e.g. solid tumors, lymphomas, leukemia and breast cancer. Doxorubicin is known to produce severe cytotoxicity. Metformin (Met) is a biguanide used for type 2 diabetes mellitus. Metformin have cytoprotective effect in addition to reducing basal and postprandial levels of glucose by decreasing the production of ROS, maintaining energy homeostasis and apoptosis regulation by its activation of adenosine monophosphate-activated protein kinase (AMPK). Met has also the ability to increase apoptotic factors and suppression of proliferation thus MET consider as cytotoxic and anti-proliferative drug. Objectives: This study was designed to investigate the cytotoxic and antiproliferative effect of Met comparing to DOX as a control in RD cell, also combination of both. Materials and Methods: Cell lines that used (Epithelial cells as a normal cell line and RD cell line was taken from human breast cancer) cultured in suitable media potentiated with different concentrations of heat-inactivated human serum. MTT assay (3-(4,5-Dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide) using for detection of cytotoxicity in Epithelial and RD cell lines for duration 72hrs. Results: The results showed that treatment with DOX, MET and combination DOX with MET there is significant (p≤ 0.5) cytotoxic, apoptotic and antiproliferative effect and there is potentiation effect between MET and DOX on tumor cells when treated by combination DOX with MET also Met showed a valuable cytotoxic effect through the detection of IC50. Conclusion: From the results, it can be concluded that Metformin have a good cytotoxic and antiproliferative effect on tumor cell lines.
Acute kidney injury (AKI), formly known as acute renal failure (ARF), is an abrupt and reversible decrease in kidney function as indicated by the glomerular filtration rate (GFR). Diclofenac-induced AKI is due to toxic effect of it on renal glomeruli, resulting in glomerular lesions. Furthermore, diclofenac causes autolysis, which increase renal intracellular osmolarity that leads to proximal renal tubular dilatations. Lipoic acid (LA) has antioxidant and anti-inflammatory activities. Bosentan is a competitive endothelin A (ETA) and endothelin B (ETB) receptors antagonist. In this study, the evaluation of effectiveness of lipoic acid and bosentan against diclofenac-induced AKI was done by histopathological examination. The results showed that diclofenac caused histopathological changes include; retracted glomerulus, tubular cast, tubule-interstitial inflammation and tubular necrosis. Lipoic acid or bosentan alone could not reduce the histopathological alterations caused by diclofenac. Meanwhile, the combination therapy was able to reduce the histopathological changes significantly (p>0.05). Therefore, the combination therapy of lipoic acid and bosentan showed promising ameliorative effect against diclofenac-induced AKI
Toxoplasmosis is one of the most globally prevalent zoonotic infection caused by an obligate, intracellular parasite called Toxoplasma gondii. Toxoplasmosis actively triggers an acute immune response and inflammatory reactions, which causes serious pathological changes in various tissues in the human body, and more evidently localizes in different nervous tissues of various body organs. The YKL-40 is a glycoprotein secreted by numerous cell types in different patterns associated with various pathological processes such as inflammatory reactions, tissue remodeling, and fibrosis, and is a disease-specific biomarker of neuroinflammation. Therefore, this study aimed to determine whether the YKL-40 is markedly increased in toxoplasmosis or not and whether its level is different between the acute and chronic phases of the infection to determine if it can be used as a clinically useful biomarker in the diagnosis, and determination of disease severity and follow-up of toxoplasmosis. Accordingly, a total of 80 serum samples were collected from previously diagnosed female patients of different ages with toxoplasmosis. In addition, serum samples of 10 healthy females were used as the control. Patients were first divided into two groups (30 patients with acute infection, and 50 patients with chronic infection) depending on the results of detection of specific anti-Toxoplasma IgM and IgG by enzymelinked immunosorbent assay (ELISA). The level of YKL-40 was then measured in the patients' serum by ELISA. The statistical analysis of data clearly disclosed very highly significant differences (P < 0.001) between the level of YKL-40 in the acute infection group and healthy controls, chronic infection group and healthy controls, and between the groups with acute and chronic infections. These findings led to conclude that YKL-40 classify as a unique and sophisticated biomarker in the diagnosis of toxoplasmosis where it can vitally be used to detect the stage of the disease, whether acute or chronic, besides its ability to detect the infection.
Conocarpus erectus L. is a perennial, evergreen shrub belonging to Combretaceae family. Conocarpus plant reported to contain phenolic acid, flavonoids, lignan, terpenes and tannins. Aim of study was to isolate lupeol from hexane fraction and gallic acid from ethyl acetate fraction and investigate the effects of (hexane and ethyl acetate) fractions on viability of pancreatic AsPC-1 and breast MCF-7 cell lines by MTT assay. The presence of lupeol in the hexane and gallic acid in the ethyl acetate extracts was detected by TLC. The identification of isolated lupeol and gallic acid by HPTLC and HPLC comparing with standard lupeol and gallic acid. Structural elucidation of isolated compounds done by FTIR and UV spectrophotometer. The cytotoxic activity showed more at high concentration (30µg/ml) in both ethyl acetate and hexane fractions against MCF-7 cell line, the percentage of cellular inhibition for ethyl acetate at 30mg/ml was (73% and 79%) more than the hexane fraction in which the inhibition was (60% and 76%) at 48hr and 72 hr respectively. Furthermore, the cytotoxic activity more at high concentration (30µg/ml) in both fractions against AsPC-1 cell line with cellular inhibition (58% and 70%) for ethyl acetate fraction and (50% and 66%) for hexane fraction in compared with Cisplatin.
<p><strong>Objective: </strong>The aim of this study was to investigate the capability of <em>Zizyphus spina christi</em> methanol extract to inhibit cancer cell line proliferation.</p><p><strong>Methods: </strong>The leaves of <em>Zizyphus spina christi</em> were extracted by cold maceration method. The anti-proliferative activity of the methanol extract against rhabdomyosarcoma (RD) cell line was tested by 3-(4, 5 Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The phytochemical constituents were identified by gas chromatography-mass spectrometry (GC-MS) analysis. The antioxidant activity was assessed by measuring free radical scavenging activity using 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay. <strong></strong></p><p><strong>Results: </strong>The percentage extraction yield for leaves with methanol was 20.64%. The methanol extract showed dose dependent inhibition of RD cell line, the IC<sub>50</sub> was 154.44 µg/ml. GC-MS showed the presence of flavonoid fraction and other compounds with antioxidant activity. The methanol extract demonstrated DPPH scavenging activity with IC<sub>50</sub> of 33.91 mg/ml.</p><p><strong>Conclusion: </strong>Methanol extract showed<strong> </strong>potential anti-proliferative activity against RD cell line,<strong> </strong>which could be due to its antioxidant activity.</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.